BioInvent International AB (BOVNF) (BOVNF)

[ancientacid]

http://www.baystreet.ca/articles/research_reports/lifesci/BioInvent022117.pdf

BioInvent (BINV.ST)
Initiation Report

LifeSci Investment Abstract
BioInvent (NasdaqStockholm: BINV.ST) is a biopharmaceutical company developing cancer
therapeutics using its wholly-owned antibody drug discovery platform. The Company
currently has 4 product candidates in clinical development with novel mechanisms of action.
Lead candidate BI-1206 is an antibody targeting CD32b, which is expressed in several B-cell
malignancies and is associated with resistance to rituximab, the standard of care. A Phase I/
IIa study with BI-1206 in relapsed/refractory non-Hodgkin lymphoma (NHL) and chronic
lymphocytic leukemia (CLL) is ongoing, and initial data are expected in the first half of
2018. Secondary asset TB-403 targets the placental growth factor (PlGF) protein to inhibit
neuropilin 1 (Nrp1) signaling. It is being evaluated in a Phase I/II study for medulloblastoma,
a rare form of brain cancer that mostly affects children. Additional clinical candidates include
THR-317 for diabetic macular edema, and BI-505 for multiple myeloma. BioInvent’s n-
CoDeR/F.I.R.S.T developmental platform is validated by research collaborations with leading
pharmaceutical companies that include Pfizer, Bayer, Daiichi-Sankyo, Servier, Mitsubishi
Tanabe Pharma, and Xoma.